| CAS NO: | 66104-23-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 410.59 |
|---|---|
| Formula | C19H26N2S.CH4O3S |
| CAS No. | 66104-23-2 (mesylate); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mg/mL (24.35 mM) |
| Water: 82 mg/mL (199.71 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate InChi Key: UWCVGPLTGZWHGS-ZORIOUSZSA-N InChi Code: InChI=1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1 SMILES Code: [H][C@@]1(N(CCC)C[C@H](CSC)C[C@@]12[H])CC3=CNC4=C3C2=CC=C4.CS(=O)(O)=O |
| Synonyms | LY127809; Pergolide methanesulfonate; LY-127809; LY 127809 |
| In Vitro | In vitro activity: Pergolide mesylate (trade name Permax) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Pergolide mesylate functions as an agonist at the dopamine D2, D1 and serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It may possess agonist activity at other dopamine receptor subtypes as well, similar to cabergoline. |
|---|---|
| In Vivo | Pergolide mesylate decreases plasma prolactin concentrations. The weak agonist activity of pergolide at D1 receptors somewhat alters its clinical and side effect profile in the treatment of Parkinson's disease. The drug is in decreasing use, as it is reported to be associated with a form of heart disease called cardiac fibrosis. The use of pergolide or cabergoline is associated with a significantly increased risk of newly diagnosed cardiac-valve regurgitation. |
| Animal model | |
| Formulation & Dosage | |
| References | Science. 1979 Sep 14;205(4411):1151-3; Br Med J (Clin Res Ed). 1983 Apr 9; 286(6372): 1177–1179. |
m.cnreagent.com